Ignite Creation Date:
2024-05-05 @ 5:20 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00432666
Status:
COMPLETED
Last Update Posted:
2010-12-15
First Post:
2007-02-07
Brief Title:
IncobotulinumtoxinA Xeomin Versus Placebo in the Treatment of Post-stroke Spasticity of the Upper Limb
Sponsor:
Merz Pharmaceuticals GmbH
Organization:
Merz Pharmaceuticals GmbH
Study Overview
Official Title:
Prospective Double-blind Placebo-controlled Randomized Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA Xeomin in the Treatment of Post-stroke Spasticity of the Upper Limb
Status:
COMPLETED
Status Verified Date:
2010-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
IncobotulinumtoxinA Xeomin is a botulinum toxin type A preparation free from complexing proteins ie free from proteins other than the active toxin Injected into the muscle incobotulinumtoxinA Xeomin causes local weakening Botulinum toxin type A is widely used for treatment of various neurological conditions This study will investigate the efficacy and safety of incobotulinumtoxinA Xeomin in the treatment of post-stroke spasticity of the upper limb
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None